Paper Details

  1. Home
  2. Paper Details

Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.

Author: BenjaponpitakSuwat, ChokephaibulkitKulkanya, ChuenkitmongkolSunate, KosalaraksaPope, PancharoenChitsanu, ThisyakornUsa

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A randomized, controlled phase III study evaluated the immunogenicity and safety of PPV23 as a booster dose in toddlers primed with PCV7. Boosting with PPV23 was immunogenic and well tolerated, leading to higher antibody concentrations against certain serotypes compared to PCV7.
Paper Details　
Original Abstract of the Article :
The current study examined the safety and immunogenicity of 23-valent pneumococcal capsular polysaccharide vaccine (Pneumo23(®) [PPV23], Sanofi Pasteur) as a booster dose in 12- to 18-month-old children primed with heptavalent pneumococcal vaccine (PCV7; Prevnar(®), Pfizer). This was a randomized, o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186054/

データ提供：米国国立医学図書館（NLM）

Boosting Immunity: The Role of Pneumococcal Vaccines

Pneumococcal disease is a serious health concern, particularly for young children. This research examines the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine (PPV23) as a booster dose in children who had received the 3-dose primary series of a 7-valent pneumococcal conjugate vaccine (PCV7). The researchers found that PPV23 was both safe and immunogenic, providing additional protection against pneumococcal disease.

PPV23: A Powerful Boost to Immunity

This research is like discovering a new source of water in a dry desert – a vital resource that can replenish and strengthen the body's defenses. The study found that PPV23 provided a significant boost to the immune system, offering additional protection against pneumococcal disease. This finding is encouraging news for parents and healthcare providers, as it provides another layer of protection for children.

Protecting Children: A Collaborative Effort

This research highlights the importance of collaboration between scientists, healthcare providers, and parents in protecting children from serious diseases. It is like a journey through the desert, where a shared sense of purpose and teamwork are essential for survival. This study is a testament to the ongoing efforts to develop safe and effective vaccines that can protect children from preventable diseases. It also underscores the importance of vaccination in ensuring the health and well-being of our children.

Dr. Camel's Conclusion

This study provides reassuring evidence that PPV23 is both safe and effective as a booster dose for children who have already received the PCV7 vaccine. It's a reminder that we are constantly making progress in the field of vaccination, developing new and improved vaccines to protect our children from infectious diseases. This research is a testament to the power of science and medicine in safeguarding our children's health and well-being.

Date :
  1. Date Completed 2015-07-09
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

25424793

DOI: Digital Object Identifier

PMC4186054

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.